Synairgen’s inhaled COVID-19 treatment included in US trial
Trial is sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID)
Read More
Tag: US government
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
